Global Retirement Partners LLC Decreases Stock Position in GE HealthCare Technologies Inc. (NASDAQ:GEHC)

Global Retirement Partners LLC lessened its stake in GE HealthCare Technologies Inc. (NASDAQ:GEHC) by 12.3% in the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 9,843 shares of the company’s stock after selling 1,376 shares during the quarter. Global Retirement Partners LLC’s holdings in GE HealthCare Technologies were worth $770,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. LGT Financial Advisors LLC boosted its holdings in GE HealthCare Technologies by 1,673.3% in the 3rd quarter. LGT Financial Advisors LLC now owns 266 shares of the company’s stock worth $25,000 after acquiring an additional 251 shares during the period. Capital Performance Advisors LLP purchased a new position in GE HealthCare Technologies in the 3rd quarter worth approximately $26,000. Ashton Thomas Securities LLC purchased a new position in GE HealthCare Technologies in the 3rd quarter worth approximately $26,000. Darwin Wealth Management LLC purchased a new position in GE HealthCare Technologies in the 3rd quarter worth approximately $31,000. Finally, Continuum Advisory LLC boosted its stake in shares of GE HealthCare Technologies by 101.8% during the 3rd quarter. Continuum Advisory LLC now owns 333 shares of the company’s stock valued at $31,000 after buying an additional 168 shares during the last quarter. Hedge funds and other institutional investors own 82.06% of the company’s stock.

GE HealthCare Technologies Stock Performance

GEHC stock opened at $91.09 on Friday. The company has a current ratio of 1.04, a quick ratio of 0.83 and a debt-to-equity ratio of 0.88. The firm has a market cap of $41.66 billion, a P/E ratio of 21.04, a P/E/G ratio of 3.19 and a beta of 1.15. GE HealthCare Technologies Inc. has a 12-month low of $74.51 and a 12-month high of $94.80. The stock’s 50 day simple moving average is $85.05 and its 200 day simple moving average is $85.86.

GE HealthCare Technologies (NASDAQ:GEHC) last posted its quarterly earnings results on Thursday, February 13th. The company reported $1.45 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.26 by $0.19. The business had revenue of $5.32 billion for the quarter, compared to analyst estimates of $5.33 billion. GE HealthCare Technologies had a return on equity of 25.74% and a net margin of 10.13%. As a group, equities research analysts predict that GE HealthCare Technologies Inc. will post 4.68 EPS for the current year.

Analysts Set New Price Targets

Several equities analysts have recently commented on the company. Citigroup increased their target price on GE HealthCare Technologies from $103.00 to $110.00 and gave the company a “buy” rating in a research note on Thursday, February 13th. Jefferies Financial Group upgraded GE HealthCare Technologies from a “hold” rating to a “buy” rating and increased their target price for the company from $95.00 to $103.00 in a research note on Wednesday, January 8th. Finally, Wells Fargo & Company increased their target price on GE HealthCare Technologies from $96.00 to $103.00 and gave the company an “overweight” rating in a research note on Friday, February 14th. One analyst has rated the stock with a sell rating, three have given a hold rating, eight have given a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $97.67.

About GE HealthCare Technologies

GE HealthCare Technologies Inc engages in the development, manufacture, and marketing of products, services, and complementary digital solutions used in the diagnosis, treatment, and monitoring of patients in the United States, Canada, and internationally. The company operates through four segments: Imaging, Ultrasound, Patient Care Solutions, and Pharmaceutical Diagnostics.